Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Human papillomavirus 16-positive (HPV16+) cancers: Overview
Human papillomavirus 16-positive (HPV16+) cancer is a type of cancer that is caused due to the infection of HPV virus. The infection can lead to 70% of cervical cancers and to some extent squamous cell head and neck cancer. This cancer is more prevalent among women than men and can be sexually transmitted. Individual with weakened immune system, co-infection with other STDs agents are more likely to progress to pre cancer, and cancer associated to HPV virus infection.
“Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape is provided which includes the disease overview and Human papillomavirus 16-positive (HPV16+) cancers treatment guidelines. The assessment part of the report embraces, in depth Human papillomavirus 16-positive (HPV16+) cancers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human papillomavirus 16-positive (HPV16+) cancers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Human papillomavirus 16-positive (HPV16+) cancers R&D. The therapies under development are focused on novel approaches to treat/improve Human papillomavirus 16-positive (HPV16+) cancers.
Human papillomavirus 16-positive (HPV16+) cancers Emerging Drugs Chapters
This segment of the Human papillomavirus 16-positive (HPV16+) cancers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Human papillomavirus 16-positive (HPV16+) cancers Emerging Drugs
VB 10.16: Vaccibody AS
Vaccibody AS’ lead drug candidate, VB 10.16 is a therapeutic DNA vaccine in the development for the treatment of HPV16+ induced pre- malignancies and malignancies. The drug has demonstrated favorable outcome in its phase I trial. It induces immunologic cytotoxicity to curb the cancer progression.
GX 188E: Genexine
Genexine “breakthrough” drug GX 188E is a DNA therapeutic vaccine which is currently being evaluated for the treatment of HPV 16+ associated cancer. The drug target and activate dendritic cells and induce tumor-specific CD8+ immune response.
Further product details are provided in the report……..
Human papillomavirus 16-positive (HPV16+) cancers: Therapeutic Assessment
This segment of the report provides insights about the different Human papillomavirus 16-positive (HPV16+) cancers drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Human papillomavirus 16-positive (HPV16+) cancers
There are approx. 10+ key companies which are developing the therapies for Human papillomavirus 16-positive (HPV16+) cancers. The companies which have their Human papillomavirus 16-positive (HPV16+) cancers drug candidates in the most advanced stage, i.e. phase II include, Vaccibody AS.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Human papillomavirus 16-positive (HPV16+) cancers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Human papillomavirus 16-positive (HPV16+) cancers: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human papillomavirus 16-positive (HPV16+) cancers therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human papillomavirus 16-positive (HPV16+) cancers drugs.
Human papillomavirus 16-positive (HPV16+) cancers Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Human papillomavirus 16-positive (HPV16+) cancers: Overview
Human papillomavirus 16-positive (HPV16+) cancer is a type of cancer that is caused due to the infection of HPV virus. The infection can lead to 70% of cervical cancers and to some extent squamous cell head and neck cancer. This cancer is more prevalent among women than men and can be sexually transmitted. Individual with weakened immune system, co-infection with other STDs agents are more likely to progress to pre cancer, and cancer associated to HPV virus infection.
“Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape is provided which includes the disease overview and Human papillomavirus 16-positive (HPV16+) cancers treatment guidelines. The assessment part of the report embraces, in depth Human papillomavirus 16-positive (HPV16+) cancers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human papillomavirus 16-positive (HPV16+) cancers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Human papillomavirus 16-positive (HPV16+) cancers R&D. The therapies under development are focused on novel approaches to treat/improve Human papillomavirus 16-positive (HPV16+) cancers.
Human papillomavirus 16-positive (HPV16+) cancers Emerging Drugs Chapters
This segment of the Human papillomavirus 16-positive (HPV16+) cancers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Human papillomavirus 16-positive (HPV16+) cancers Emerging Drugs
VB 10.16: Vaccibody AS
Vaccibody AS’ lead drug candidate, VB 10.16 is a therapeutic DNA vaccine in the development for the treatment of HPV16+ induced pre- malignancies and malignancies. The drug has demonstrated favorable outcome in its phase I trial. It induces immunologic cytotoxicity to curb the cancer progression.
GX 188E: Genexine
Genexine “breakthrough” drug GX 188E is a DNA therapeutic vaccine which is currently being evaluated for the treatment of HPV 16+ associated cancer. The drug target and activate dendritic cells and induce tumor-specific CD8+ immune response.
Further product details are provided in the report……..
Human papillomavirus 16-positive (HPV16+) cancers: Therapeutic Assessment
This segment of the report provides insights about the different Human papillomavirus 16-positive (HPV16+) cancers drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Human papillomavirus 16-positive (HPV16+) cancers
There are approx. 10+ key companies which are developing the therapies for Human papillomavirus 16-positive (HPV16+) cancers. The companies which have their Human papillomavirus 16-positive (HPV16+) cancers drug candidates in the most advanced stage, i.e. phase II include, Vaccibody AS.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Human papillomavirus 16-positive (HPV16+) cancers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Vaccines
- Small molecule
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Human papillomavirus 16-positive (HPV16+) cancers: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human papillomavirus 16-positive (HPV16+) cancers therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human papillomavirus 16-positive (HPV16+) cancers drugs.
Human papillomavirus 16-positive (HPV16+) cancers Report Insights
- Human papillomavirus 16-positive (HPV16+) cancers Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Human papillomavirus 16-positive (HPV16+) cancers drugs?
- How many Human papillomavirus 16-positive (HPV16+) cancers drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Human papillomavirus 16-positive (HPV16+) cancers?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Human papillomavirus 16-positive (HPV16+) cancers therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Human papillomavirus 16-positive (HPV16+) cancers and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vaccibody As
- Genexine
- Transgene
- Inovio Pharmaceuticals
- VB10.16
- GX 188E
- TG4001
- MEDI0457
Introduction
Executive Summary
Human papillomavirus 16-positive (HPV16+) cancers: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Human papillomavirus 16-positive (HPV16+) cancers – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Human papillomavirus 16-positive (HPV16+) cancers companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Human papillomavirus 16-positive (HPV16+) cancers Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
VB 10.16: Vaccibody As
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
GX 188E: Genexine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Human papillomavirus 16-positive (HPV16+) cancers Key Companies
Human papillomavirus 16-positive (HPV16+) cancers Key Products
Human papillomavirus 16-positive (HPV16+) cancers- Unmet Needs
Human papillomavirus 16-positive (HPV16+) cancers- Market Drivers and Barriers
Human papillomavirus 16-positive (HPV16+) cancers- Future Perspectives and Conclusion
Human papillomavirus 16-positive (HPV16+) cancers Analyst Views
Human papillomavirus 16-positive (HPV16+) cancers Key Companies
Appendix
Executive Summary
Human papillomavirus 16-positive (HPV16+) cancers: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Human papillomavirus 16-positive (HPV16+) cancers – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Human papillomavirus 16-positive (HPV16+) cancers companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Human papillomavirus 16-positive (HPV16+) cancers Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
VB 10.16: Vaccibody As
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
GX 188E: Genexine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Human papillomavirus 16-positive (HPV16+) cancers Key Companies
Human papillomavirus 16-positive (HPV16+) cancers Key Products
Human papillomavirus 16-positive (HPV16+) cancers- Unmet Needs
Human papillomavirus 16-positive (HPV16+) cancers- Market Drivers and Barriers
Human papillomavirus 16-positive (HPV16+) cancers- Future Perspectives and Conclusion
Human papillomavirus 16-positive (HPV16+) cancers Analyst Views
Human papillomavirus 16-positive (HPV16+) cancers Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Human papillomavirus 16-positive (HPV16+) cancers
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Human papillomavirus 16-positive (HPV16+) cancers
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Human papillomavirus 16-positive (HPV16+) cancers
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Human papillomavirus 16-positive (HPV16+) cancers
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
